<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418599</url>
  </required_header>
  <id_info>
    <org_study_id>PK-06-107</org_study_id>
    <nct_id>NCT01418599</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions</brief_title>
  <official_title>An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets vs. Sanofi's Uroxatral ER Tablets in Healthy Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective:

      Primary objective of the present study was to assess the relative bioavailability of two
      formulations of Extended Release Alfuzosin 10 mg under Fed conditions, in healthy adult male
      subjects after an oral administration with 7 days washout period.

      Study Design:

      Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence
      Study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>bioequivalence based on Composite of Pharmacokinetics</measure>
    <description>bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.</description>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Alfuzosin Extended Release Tablet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The volunteers were included in the study based on the following criteria:

               -  Sex: male.

               -  Age: 18 - 45 years. .

               -  Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.

               -  Healthy and willing to participate in the study.

               -  Volunteer willing to adhere to the protocol requirements and to provide written
                  informed consent.

               -  Non-smokers or smoker who smokes less than 10 cigarettes per day

        Exclusion Criteria:

          -  The volunteers were excluded from the study based on the following criteria:

               -  Clinically relevant abnormalities in the results of the laboratory screening
                  evaluation.

               -  Clinically significant abnormal ECG or Chest X-ray.

               -  Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic
                  blood pressure less than 60 mm Hg or more than 90 mm Hg.

               -  Pulse rate less than 50/minute or more than 100/minute.

               -  Oral temperature less than 95°P or more than 98.6°P.

               -  Respiratory rate less than 12/minute or more than 20/minute

               -  History of allergy to the test drug or any drug chemically similar to the drug
                  under investigation.

               -  History of alcohol or drug abuse

               -  Positive breath alcohol test

               -  Recent history of kidney or liver dysfunction.

               -  History of consumption of prescribed medication since last 14 days or OTC
                  medication since last 07 days before beginning of the study.

               -  Volunteers suffering from any chronic illness such as arthritis, asthma etc.

               -  History of heart failure.

               -  HIV, HCV, HBsAg positive volunteers.

               -  Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, - - -
                  Cocaine positive volunteers based on urine test.

               -  Volunteers suffering from any psychiatric (acute or chronic) illness requiring
                  medications.

               -  Administration of any study drug in the period 0 to 3 months before entry to the
                  study.

               -  History of significant blood loss due to any reason, including blood donation in
                  the past 3 months.

               -  History of pre-existing bleeding disorder.

               -  Existence of any surgical or medical condition, which, in the judgment of the
                  chief investigator and/or clinical investigator/physician, might interfere with
                  the absorption, distribution, metabolism or excretion of the drug or likely to
                  compromise the safety of volunteers.

               -  Inability to communicate or co-operate due to language problem, poor mental
                  development or impaired cerebral function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Bio Evaluation Centre, Torrent Pharmaceuticals Ltd.,</name>
      <address>
        <city>Village Bhat, Gandhinagar</city>
        <state>Gujarat</state>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Investigator</name_title>
    <organization>Torrent Pharmaceuticals Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

